Ticker > Company >

Laurus Labs share price

Laurus Labs Ltd.

NSE: LAURUSLABS BSE: 540222 SECTOR: Pharmaceuticals & Drugs  2.98 L   1.9 K   496

960.90
+1.25 (0.13%)
BSE: Today, 01:36 PM

Price Summary

Today's High

₹ 970

Today's Low

₹ 956

52 Week High

₹ 962.3

52 Week Low

₹ 474.25

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

51871.77 Cr.

Enterprise Value

54145.77 Cr.

No. of Shares

53.98 Cr.

P/E

75.97

P/B

10.55

Face Value

₹ 2

Div. Yield

0.13 %

Book Value (TTM)

₹  91.11

CASH

50.64 Cr.

DEBT

2324.64 Cr.

Promoter Holding

27.59 %

EPS (TTM)

₹  12.65

Sales Growth

8.41%

ROE

8.72 %

ROCE

10.44%

Profit Growth

70.04 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Laurus Labs Ltd.

Lasinone Trilawil Prolavir LR Trilavir Mini Myvajra

Index Presence

The company is present in 29Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.41%
3 Year3.49%
5 Year13.28%

Profit Growth

1 Year70.04%
3 Year-20.25%
5 Year7.33%

ROE%

1 Year8.72%
3 Year11.55%
5 Year20.32%

ROCE %

1 Year10.44%
3 Year13.42%
5 Year20.48%

Debt/Equity

0.5123

Price to Cash Flow

96.05

Interest Cover Ratio

3.7651

CFO/PAT (5 Yr. Avg.)

1.17159121624922

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 27.59 2.69
Jun 2025 27.59 2.69
Mar 2025 27.62 2.69
Dec 2024 27.62 2.69
Sep 2024 27.18 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 23.6628477357467% in the last 5 years.
  • The company has a good cash flow management; CFO/PAT stands at 1.17159121624922.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.46757215951611.

 Limitations

  • The company has shown a poor profit growth of -20.2546738551189% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.48806787274689% for the Past 3 years.
  • The company is trading at a high PE of 75.97.
  • The company is trading at a high EV/EBITDA of 37.0165.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Net Sales 1184.85 1265.19 1650.01 1432.75 1566.6
Total Expenditure 1003.02 1058.91 1255.18 1105.37 1176.94
Operating Profit 181.83 206.28 394.83 327.38 389.66
Other Income 11.89 7.12 72.16 21.52 28.45
Interest 44.69 48.02 48.6 43.89 33.68
Depreciation 90.94 88.66 88.19 93.57 95.59
Exceptional Items 0 0 0 0 0
Profit Before Tax 58.09 76.72 330.2 211.44 288.84
Tax 15.65 19.45 78.3 53.5 73.17
Profit After Tax 42.44 57.27 251.9 157.94 215.67
Adjusted EPS (Rs) 0.79 1.06 4.67 2.93 4

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 4768.72 4707.04 5773.45 4812.39 5216.98
Total Expenditure 3258.85 3421.84 4291.69 4062.51 4272.65
Operating Profit 1509.87 1285.2 1481.76 749.88 944.33
Other Income 27.32 21.55 15.95 47.42 100.47
Interest 65.92 95.86 145.7 150.82 182.2
Depreciation 196.64 235.48 300.58 345.01 358.79
Exceptional Items 0 0 0 0 0
Profit Before Tax 1274.63 975.41 1051.43 301.47 503.81
Tax 318.52 225.32 291.05 77.77 123.42
Net Profit 956.11 750.09 760.38 223.7 380.39
Adjusted EPS (Rs.) 17.82 13.96 14.12 4.15 7.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 107.32 107.47 107.73 107.79 107.85
Total Reserves 2604.92 3280.74 3949.09 4099.26 4456.1
Borrowings 382.64 549.67 565.49 490.53 414.25
Other N/C liabilities 178.68 236.55 229.33 234.11 446.51
Current liabilities 2696.26 2899.57 2844.09 3545.04 4109.3
Total Liabilities 5969.82 7074 7695.73 8476.73 9534.01
Assets
Net Block 1818.04 2186.23 2884.16 3036.31 2887.5
Capital WIP 324.17 755.03 357.06 155.51 336.24
Intangible WIP 0 0 0 0 0
Investments 318.89 361.72 384.12 634.87 740.22
Loans & Advances 91.84 69.82 132.84 292.11 591.9
Other N/C Assets 30.8 31.16 28.52 31.57 24.11
Current Assets 3386.08 3670.04 3909.03 4326.36 4954.04
Total Assets 5969.82 7074 7695.73 8476.73 9534.01
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1274.63 975.41 1051.43 301.47 503.81
Adjustment 240.43 322.36 442.51 478.32 498.63
Changes in Assets & Liabilities -594.55 -308.46 -344.26 -23.27 -327.99
Tax Paid -226.06 -166.34 -268.13 -97.98 -134.39
Operating Cash Flow 694.45 822.97 881.55 658.54 540.06
Investing Cash Flow -899.68 -836.61 -735.27 -756.74 -591.65
Financing Cash Flow 243.13 15.19 -185.19 139.41 59.32
Net Cash Flow 37.9 1.55 -38.91 41.21 7.73

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 27.18 27.62 27.62 27.59 27.59
chandrakanth chereddi 0.01 0.01 0.01 0.01 0.01
chava narasimha rao 0.02 0.02 0.02 0.02 0.02
chunduru venkata lakshman... 2.49 2.65 2.65 2.65 2.65
hymavathi vantaram 0.04 0.04 0.04 0.04 0.04
kamala kommana 0.02 0.02 0.02 0.02 0.02
krishnaveni vasireddi 0.04 0.04 0.04 0.04 0.04
m/s. leven holdings (repr... 1.24 1.24 1.24 1.24 1.24
m/s. nsn holdings (repres... 23.02 23.02 23.02 22.99 22.99
nagamani thokala 0.02 0.02 0.02 0.02 0.02
narasimha rao suryadevara... 0.03 0.03 0.03 0.03 0.03
rama suryadevara 0.03 0.03 0.03 0.03 0.03
satyanarayana chava - 0.29 0.29 0.29 0.29
sekhar babu chunduru 0.02 0.02 0.02 0.02 0.02
venkata ravi kumar vantar... 0.19 0.19 0.19 0.19 0.19
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 72.82 72.38 72.38 72.41 72.41
akash bhanshali 1.33 1.33 1.33 1.32 1.32
anukar projects private l... 3.24 3.24 3.24 3.24 3.24
barclays wealth trustees ... 1.14 1.14 1.14 1.61 1.61
kotak funds - india midca... 1.39 1.39 1.16 1.13 1.11
life insurance corporatio... 2.70 2.70 2.70 2.17 1.34
mirae asset nifty500 mult... - - - - 2.74
new world fund inc 6.50 6.50 6.50 6.49 6.49
sbi nifty 500 index fund - - - - 1.35
smallcap world fund, inc 4.09 4.25 4.25 4.25 4.25
sbi arbitrage opportuniti... - - 1.82 1.64 -
dsp arbitrage fund - - 1.16 - -
goldman sachs funds - gol... - 1.18 1.18 - -
vanguard total internatio... 1.00 1.00 1.02 - -
dsp equity opportunities ... - 1.25 - - -
sbi large & midcap fund 2.53 2.11 - - -
amansa holdings private l... 2.14 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CARE
Credit FITCH
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY21
Concall Q4FY20
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY24
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY26
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY22
Presentation Q1FY21
Presentation H1FY24

Company News

Laurus Labs reports around 10-fold jump in Q2 consolidated net profit 24 Oct, 10:08 AM Laurus Labs - Quaterly Results 24 Oct, 12:00 AM Laurus Labs informs about presentation 23 Oct, 5:16 PM Laurus Labs informs about press release 23 Oct, 5:15 PM Laurus Labs informs about investor presentation 12 Sep, 4:59 PM Laurus Labs receives 531.77 acres of land from Government of Andhra Pradesh 28 Jul, 12:37 PM Laurus Labs - Quaterly Results 25 Jul, 3:06 PM Laurus Labs - Quaterly Results 25 Jul, 3:06 PM Laurus Labs - Quaterly Results 25 Jul, 3:06 PM Laurus Labs invests Rs 39.99 crore in Laurus Bio 26 Jun, 3:08 PM Laurus Labs informs about investor conference 12 Jun, 5:27 PM Laurus Labs - Quaterly Results 24 Apr, 3:00 PM Laurus Labs - Quaterly Results 24 Apr, 3:00 PM Laurus Labs - Quaterly Results 24 Apr, 3:00 PM Laurus Labs gets EIR for API manufacturing facility in Andhra Pradesh 15 Apr, 2:18 PM Laurus Labs gets nod to acquire up to 26% stake in Kurnool Renewables 28 Mar, 4:40 PM Laurus Labs acquires equity shares in KRKA 17 Mar, 11:22 AM Laurus Labs - Quaterly Results 24 Jan, 2:58 PM Laurus Labs - Quaterly Results 24 Jan, 2:58 PM Laurus Labs - Quaterly Results 24 Jan, 2:58 PM Laurus Labs’ arm gets one observation from USFDA 23 Jan, 11:58 AM Laurus Labs’ arm secures equity investments from Eight Roads Ventures, F-Prime Capital, Laurus Labs 9 Dec, 10:50 AM Laurus Labs submits analyst meet intimation 7 Nov, 12:43 PM Laurus Labs informs about standalone and consolidated financial results 24 Oct, 5:21 PM Laurus Labs - Quaterly Results 24 Oct, 3:11 PM Laurus Labs - Quaterly Results 24 Oct, 3:11 PM Laurus Labs - Quaterly Results 24 Oct, 3:11 PM Laurus Labs inaugurates new R&D facility 16 Sep, 2:59 PM Laurus Labs completes USFDA Audit for API Manufacturing Facility at Hyderabad 14 Sep, 4:47 PM Laurus Labs - Quaterly Results 25 Jul, 2:54 PM Laurus Labs - Quaterly Results 25 Jul, 2:54 PM Laurus Labs - Quaterly Results 25 Jul, 2:54 PM Laurus Labs informs about analyst meet 19 Jul, 5:12 PM Laurus Labs informs about press release 19 Jun, 4:32 PM Laurus Labs informs about disclosures 11 Jun, 4:29 PM Laurus Lab informs about approval of audited financial results 25 Apr, 5:12 PM Laurus Labs informs about investors presentation 25 Apr, 4:50 PM Laurus Labs informs about press release 25 Apr, 4:45 PM Laurus Labs reports 30% fall in Q4 consolidated net profit 25 Apr, 4:00 PM Laurus Labs - Quaterly Results 25 Apr, 3:09 PM Laurus Labs - Quaterly Results 25 Apr, 3:09 PM Laurus Labs - Quaterly Results 25 Apr, 3:09 PM USFDA completes inspection at Laurus Labs’ API manufacturing facilities 19 Apr, 6:16 PM Laurus Labs informs about closure of trading window 30 Mar, 10:16 AM Laurus Labs invests over Rs 99 crore in subsidiary 19 Feb, 12:13 PM Laurus Labs informs about updates on acquisition 17 Feb, 3:14 PM Laurus Labs submits analyst meet intimation 13 Feb, 3:56 PM Laurus Labs enters into joint venture agreement with Krka 29 Jan, 12:41 PM Laurus Labs - Quaterly Results 24 Jan, 3:28 PM Laurus Labs - Quaterly Results 24 Jan, 3:28 PM

Laurus Labs Stock Price Analysis and Quick Research Report. Is Laurus Labs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Laurus Labs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Laurus Labs has a PE ratio of 75.8724561597698 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Laurus Labs has ROA of 4.224% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Laurus Labs has a Current ratio of 1.2056.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Laurus Labs has a ROE of 8.721%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Laurus Labs has a Debt to Equity ratio of 0.5123 which means that the company has low proportion of debt in its capital.

  • Sales growth: Laurus Labs has reported revenue growth of 8.4073% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Laurus Labs for the current financial year is 18.1010853022247%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Laurus Labs is Rs 1.2 and the yield is 0.1251%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Laurus Labs is Rs 12.6482. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Laurus Labs in Ticker for free. Also, one can get the intrinsic value of Laurus Labs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Laurus Labs FAQs

Q1. What is Laurus Labs share price today?
Ans: The current share price of Laurus Labs is Rs 959.65.

Q2. What is the market capitalisation of Laurus Labs?
Ans: Laurus Labs has a market capitalisation of Rs 51804.296432535 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Laurus Labs?
Ans: The PE ratio of Laurus Labs is 75.8724561597698 and the P/B ratio of Laurus Labs is 10.5327451869201, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Laurus Labs share?
Ans: The 52-week high share price of Laurus Labs is Rs 962.7, and the 52-week low share price of Laurus Labs is Rs 474.05.

Q5. Does Laurus Labs pay dividends?
Ans: Currently, Laurus Labs pays dividends. Dividend yield of Laurus Labs is around 0.1251%.

Q6. What are the face value and book value of Laurus Labs shares?
Ans: The face value of Laurus Labs shares is Rs 2, while the book value per share of Laurus Labs is around Rs 91.1111. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Laurus Labs?
Ans: Laurus Labs has a total debt of Rs 2324.64 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Laurus Labs?
Ans: The ROE of Laurus Labs is 8.721% and ROCE of Laurus Labs is 10.4378%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Laurus Labs a good buy for the long term?
Ans: The Laurus Labs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Laurus Labs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Laurus Labs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Laurus Labs’s financials?
Ans: You can review Laurus Labs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Laurus Labs

Laurus Labs Share Price, Business Overview & Major News

Laurus Labs is a leading Indian multinational pharmaceutical and biotechnology company with a strong focus on research and development. The company is a key player in the global pharmaceutical landscape, known for its integrated business model that spans the entire value chain, from active pharmaceutical ingredients (APIs) to finished dosage forms (FDFs) and contract development and manufacturing services (CDMO).?

The Business of Laurus Labs

Founded in 2005, Laurus Labs has rapidly grown to become a globally recognized pharmaceutical company. Its business is structured around several key divisions, allowing it to serve a diverse range of clients and markets.?

  • Generics API: This is a core segment for the company. Laurus Labs is a global leader in the production of APIs for antiretroviral (ARV) therapies, which are crucial in the treatment of HIV/AIDS. The company also has a strong presence in other high-growth therapeutic areas, including oncology, cardiovascular, and anti-diabetic drugs. It supplies APIs to nine of the ten largest generic pharmaceutical companies in the world.?

  • Generics FDF (Finished Dosage Forms): Leveraging its strengths in API manufacturing, the company has successfully backward-integrated into producing finished oral solid formulations. This allows for greater control over quality and cost, making its products more competitive.?

  • CDMO (Contract Development and Manufacturing Organisation) - Synthesis: Through its subsidiary, Laurus Synthesis, the company provides comprehensive drug development and manufacturing services to global pharmaceutical, animal health, and biotech firms. This division offers end-to-end solutions, from early-stage research to commercial-scale manufacturing, with a key focus on markets in the US, EU, and Japan.?

  • Laurus Bio: The company has also made significant inroads into the biotechnology sector with the acquisition and integration of Laurus Bio. This division focuses on precision fermentation and recombinant proteins, catering to the growing demand for sustainable and bio-manufactured products in the food, health, and nutritional spaces.?

Major News & Developments

Laurus Labs is frequently in the news for its strategic initiatives, financial performance, and R&D breakthroughs. Key news and developments typically revolve around:

  • Financial Results: The market closely tracks the company's quarterly and annual financial performance, paying close attention to revenue growth in its different segments (API, FDF, CDMO), profitability, and margin trends.

  • Regulatory Approvals: Announcements regarding approvals from major regulatory bodies like the USFDA and WHO for its manufacturing facilities or new products are significant positive triggers for the company. Laurus Labs has a strong track record of regulatory compliance across its multiple manufacturing units.?

  • Capacity Expansions and Acquisitions: News related to the expansion of its manufacturing capacities, particularly in the high-growth CDMO and biotech segments, is a key indicator of its future growth plans. Strategic acquisitions to enter new therapeutic areas or technologies are also closely watched.

  • New Product Launches and R&D Pipeline: Updates on the company's R&D pipeline, including the development of new APIs and formulations, are crucial for its long-term growth prospects.

  • Global Health Initiatives: The company's role as a major supplier of ARV drugs often puts it at the center of global health discussions and partnerships aimed at increasing access to essential medicines.

What You Can Find on This Company Page

This page is your complete resource for all information related to Laurus Labs Ltd. Here’s what you can access:

  • Live Laurus Labs Share Price: Track real-time price movements and analyse historical performance with \charts.

  • In-Depth Financial Analysis: Access detailed financial statements, key ratios, and peer comparisons.

  • Shareholding Pattern: Get a clear picture of the company's ownership structure.

  • Latest News and Corporate Actions: Stay informed about the latest company announcements, analyst ratings, dividend declarations, and other market-moving news.

  • Company Overview and Business Strategy: A detailed look at the company's diverse business segments, its R&D focus, and its strategic direction for future growth.

Frequently Asked Questions (FAQs)

Q1: What are the main business segments of Laurus Labs?
Laurus Labs operates in four main segments: Generics API (Active Pharmaceutical Ingredients), Generics FDF (Finished Dosage Forms), CDMO-Synthesis (Contract Development and Manufacturing), and Biotechnology through its subsidiary, Laurus Bio.?

Q2: What is Laurus Labs known for?
The company is globally recognised as a leading manufacturer of APIs for antiretroviral (ARV) drugs used in HIV treatment. It is also a major player in the CDMO space, providing manufacturing services to top global pharmaceutical companies.?

Q3: Does Laurus Labs have a global presence?
Yes, the company has a strong global footprint, with manufacturing plants in India and subsidiaries in the US and Europe. It exports its products to customers in over 300 countries and has its facilities approved by major international regulatory agencies.

Read More
X